Innovation Sphere

Researchers

  • Asha Pillai

Communicate

Details

Project TitleiNKT Cell Expansion Protocol
Track CodeSJ-12-0033
Short DescriptionResearchers at St. Jude have developed a method for expanding human natural killer T (NKT) cells from cellular therapy sources including but not limited to peripheral blood, bone marrow, and umbilical
AbstractResearchers at St. Jude have developed a method for expanding human natural killer T (NKT) cells from cellular therapy sources including but not limited to peripheral blood, bone marrow, and umbilical cord blood. The method applies a unique stimulation technique with or without a K562 cell line transduced to express the 41BBL ligand with or without membrane-bound IL-15 (K562-41BBL-mbIL15 or K562-41BBL). This application can be applied to grow regulatory NKT cells from cellular therapy sources for use in research on these cells, and for their application in therapy of a wide variety of cancers, auto-immune disorders including but not limited to some forms of diabetes, augmentation of vaccines including but not limited to infectious and tumor-specific vaccines, and transplantation including but not limited to prevention and treatment of graft rejection and graft-versus-host disease, and treatment of post-transplant lymphoproliferative disorders. This invention has several advantages over existing technology as follows: •Much higher and consistent expansion yield than prior protocols •Ability to expand NKT cells from a variety of different cellular therapy sources for use with those cellular therapies •More consistent phenotype of the expanded cells in their ability to prevent reactions between immune cells •Significant ability of these expanded NKT cells to kill diverse subtypes of tumor cells and thus to be applied in cancer immune therapies •Current Good Manufacturing Practices (cGMP) compatibility Granted Patents or Published Applications: WO 2015/112793 Published, U.S. patent pending
 
TagsNatural killer T cells, cancer immune therapies, cellular therapy, expansion yield, tumor cells
 
Posted DateAug 31, 2017 4:21 PM

Researcher

Name
Asha Pillai

Manager

Name
Shawn Hawkins